Omega-3 fatty acids: Evidence Review

What it is

Omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are long-chain polyunsaturated fatty acids with roles in cardiovascular function, inflammatory regulation, and neurodevelopment. The body cannot synthesise EPA and DHA efficiently from shorter-chain precursors, making dietary or supplemental intake the primary source for most people.

The main dietary sources are oily fish (salmon, mackerel, sardines, herring) and, for those avoiding fish, algal oil, the original source of EPA and DHA in the marine food chain. Regular oily fish consumption provides meaningful EPA and DHA; individuals with little or no fish intake are most likely to have low omega-3 status.

What the evidence shows

Triglyceride reduction is the best-supported cardiovascular biomarker effect. High-dose EPA/DHA (2-4g/day) reliably reduces fasting triglycerides by 20-30% in individuals with elevated baseline levels. This effect is dose-dependent and well-replicated. It is a strong biomarker effect; clinical outcome relevance is uncertain and should not be assumed from the biomarker change alone.

Omega-3 index correction in individuals with low status is consistent and well-evidenced. Supplementation reliably raises the omega-3 index (EPA + DHA as a percentage of red blood cell fatty acids) in a dose-dependent manner. The index is most useful as a risk stratification and monitoring tool; it should not be treated as a validated treatment target with a proven relationship to clinical outcomes.

Cardiovascular event prevention through standard supplement use is inconsistent across major trials. REDUCE-IT (2019) showed benefit with pharmaceutical-dose EPA-only, but this finding is complicated by a controversial mineral oil placebo and is not generalisable to combined EPA/DHA supplements. STRENGTH (2020) using combined EPA/DHA at the same dose was null. VITAL (2019) showed a modest signal with 1g/day in those with low fish intake. The biological reason for the EPA-only versus EPA/DHA divergence remains unresolved.

DHA in pregnancy and early life is supported by evidence for the importance of adequate DHA intake during fetal development and lactation. Algal DHA is accepted as bioequivalent to fish-derived DHA for this purpose in multiple regulatory contexts.

Depression as an adjunct treatment with EPA-dominant preparations shows a modest, consistent signal in diagnosed populations. Effect sizes are small to moderate and sensitive to study selection and publication bias.

What the evidence does not show

The evidence does not support general omega-3 supplementation for healthy adults with adequate dietary intake. Cognitive enhancement, general anti-inflammatory benefit, and mood improvement in replete individuals without clinical indication are not consistently demonstrated in adequately powered trials.

The cardiovascular claims that dominate omega-3 marketing substantially outrun what the current trial evidence supports for supplement-dose preparations.

Form and dose considerations

Algal oil provides EPA and DHA without the fish supply chain and is the primary choice for those avoiding animal products. Bioavailability of algal DHA is well-established as comparable to fish oil DHA. Clinical outcome equivalence between algal and fish oil has not been established in large trials and should not be assumed from bioavailability data alone.

EPA:DHA ratios vary across algal products. EPA and DHA have partially distinct biological roles, EPA more strongly associated with triglyceride reduction and inflammatory modulation; DHA with structural neural and retinal roles. Evidence from one EPA:DHA profile should not be extrapolated to products with materially different ratios.

Triglyceride-lowering effects require 2-4g/day. General dietary adequacy and omega-3 index correction can be achieved at lower doses in most individuals.

Who the evidence applies to

The evidence is most consistent for individuals with low omega-3 status, particularly those with minimal oily fish intake including vegetarians and vegans, and for specific populations including pregnant women, those with elevated triglycerides, and individuals with diagnosed depression using EPA-dominant preparations.

Healthy adults with adequate dietary intake of oily fish are unlikely to benefit meaningfully from additional supplementation. The appropriate starting point is assessment of dietary intake and, where feasible, measurement of the omega-3 index.

Safety and contraindications

Omega-3 is generally well-tolerated at standard supplement doses. At doses of 3-4g/day, there is increased bleeding risk, particularly with anticoagulant medications. An atrial fibrillation signal was observed in both REDUCE-IT and STRENGTH at 4g/day; this has not been consistently shown at lower supplement doses. GI effects including fishy aftertaste and loose stools are common and reduced by taking with food. High-dose DHA-dominant preparations may modestly raise LDL-C in some individuals.

What can reasonably be concluded

Omega-3 supplementation has clear evidence for specific outcomes in specific populations: triglyceride reduction as a biomarker effect at high doses, omega-3 index correction in low-status individuals, DHA adequacy in pregnancy, and adjunctive use in diagnosed depression with EPA-dominant preparations.

For healthy adults with adequate dietary intake, supplementation is not well-evidenced. Individual assessment of baseline status, dietary intake, life stage, and clinical context should precede any decision about supplementation and dose.